DC Healthcare (Dr Chong Clinic): What a Listed Aesthetic Clinic Chain Reveals

By Farah Zainal · Contract Manufacturing Analyst · Published 28 Sep 2026

How the company behind Dr Chong Clinic grew, lost money, turned around, and built a house skincare range, told through its Bursa Malaysia filings and NPRA records. For clinic owners, brand founders and B2B suppliers.

Article type: Company profile (business analysis) · Scope: Malaysia, medical aesthetic clinics and clinic-owned skincare · Research period: 3–25 September 2026 · Written by: Farah Zainal · Fact-checked by: Daniel Yeoh · Last reviewed: 25 September 2026 · Corrections: via the Contact page

Quick answer

DC Healthcare Holdings Berhad, the listed parent of Dr Chong Clinic, is a Bursa Malaysia ACE Market company (stock code 0283) that earns most of its money from aesthetic treatments. In-house skincare is a small share. Audited FY2025 revenue was RM87.0 million, of which aesthetic services brought in RM75.8 million (87%) and skincare products RM4.0 million (about 5%). The group made a pre-tax profit of RM1.6 million after a RM20.4 million loss in FY2024. Its house brands (newB Premium, Plant PDRN, Le Perfetto) sit under two group companies with 34 active NPRA notifications; the premium tier is made in Japan and the rest in Malaysia. This profile uses public filings only, and every number is dated. It analyses what the company discloses and is not investment advice.

Key takeaways

• Treatments pay the bills; skincare is small. Skincare products made up 4.6% of FY2025 revenue (RM3.97m of RM87.0m), according to the company’s Annual Report 2025.
• Growth came back with profit. Revenue grew 56% in FY2025. The group returned to profit from Q3 FY2025, and 1H FY2026 revenue rose 14% to RM43.98m, per company releases dated May and August 2026.
• Two sourcing routes. The premium line (newB Premium, 11 SKUs) is imported from Japan; the long-running Le Perfetto line, the newer Plant PDRN line and the body and hair items are made in Malaysia.
• Branch count depends on who counts. The AR2025 gives 23 Dr Chong Clinic outlets at end-2025. The clinic website listed 22 on 25 Sep 2026. Our Google Maps capture found 24 listings in 15 towns.
• Prepaid packages cause timing gaps. Revenue is booked when a treatment is redeemed, not when it is sold. That helps explain the FY2024 dip.

Who this is for

This profile is for clinic operators thinking about their own skincare line, brand founders and suppliers who want to see how a clinic-led brand is built and sourced, and analysts looking for a dated, sourced summary of a listed aesthetic chain. If you only need the steps to notify a product, start with our guide to cosmetic product notification with NPRA. For a listed group that entered aesthetics by acquisition rather than organic growth, read our profile of Salcon’s Bloom Healthcare. For the sector overview, comparing DC Healthcare, Bloom and 1 Doc International side by side, read Aesthetics on Bursa: what the listed players tell us about clinic skincare.

What is DC Healthcare, and how does it relate to Dr Chong Clinic?

DC Healthcare Holdings Berhad (Reg. 202201014036) is the listed holding company of the Dr Chong Clinic chain. It provides medical aesthetic, general medical and slimming/wellness services, and it sells skincare (company-stated, Annual Report 2025, p.21).

• Listing: IPO priced at 25 sen a share to raise RM49.81 million (The Edge, June 2023). It debuted on the ACE Market on 17 July 2023 and closed at 45 sen that day (The Edge). The company describes itself as the first medical aesthetic clinic chain listed on the ACE Market (company-stated, AR2025 p.5).
• Founder: Dr Chong Tze Sheng, Managing Director. The first clinic opened in Kepong, Kuala Lumpur (company-stated, AR2025 milestones).
• Operating companies named in a 24 Sep 2026 release: DC Lasers Sdn Bhd, DC Wellness Sdn Bhd, DC Lasers (Puchong) Sdn Bhd and DC Pinnacle Sdn Bhd (clinics), plus Ten Doctors Sdn Bhd, which “develops skincare products under the trading brand NewB” (release, 24 Sep 2026).
• Brands: Dr Chong Clinic, Dr Chong Slimming, NewB Premium Skincare, and DC Plus Clinic (new; first outlet in Penang, Greenlane, September 2026).
• Shariah status: classified as Shariah-compliant securities by the SC’s Shariah Advisory Council during FY2025 (company-stated, AR2025).

How many branches does Dr Chong Clinic have?

Around two dozen, with the exact count depending on the source and date. The three counts below measure slightly different things, so we show all of them.

The network covers Kuala Lumpur (Bangsar, Cheras, Kepong, Melawati, Mid Valley, Publika, TTDI, Sri Petaling), Selangor (Puchong, Klang, Shah Alam, Setia Alam, USJ), Johor (Bukit Indah, Pelangi, Taman Molek, Muar), Putrajaya, Penang, Melaka, Seremban, Ipoh and Kota Kinabalu. Kota Kinabalu, opened in 2025, took the chain into East Malaysia (AR2025).

How has DC Healthcare performed financially?

After three years of growth, revenue fell in FY2024 and the company posted a large loss. In FY2025 it recovered to record revenue and a small profit. All figures below are for years ending 31 December and come from the five-year financial highlights in the Annual Report 2025 (p.7), which shows FY2024 as restated.

Source: AR2025 p.7, audited. The earlier unaudited Q4 FY2024 interim report gave FY2024 revenue of RM55.76m and a loss before tax of RM20.01m (interim report). The small differences come from the restatement.

Why did FY2024 go wrong? The company gave two reasons in its Q4 FY2024 report. First, a “lower redemption rate in aesthetic services”, meaning patients used fewer of the prepaid treatments they had bought. Second, costs rose from expansion: more marketing, more operating cost and RM3.26m more depreciation. Aesthetic-services revenue fell 21% to RM46.28m. Contract liabilities (prepaid packages not yet used) rose to RM18.54m at 31 Dec 2024. This is the timing effect of the package model: the cash comes in when a package is sold, but the revenue only appears when the treatment is done.

What changed in FY2025? Management points to more clinics, higher redemption and cost controls (AR2025 MD&A). Revenue by segment:

Source: AR2025 MD&A, “Revenue by Segment” (p.23).

The latest quarters

For 1H FY2026, revenue was RM43.98m (up 14% from RM38.50m) and aesthetic-services revenue was RM39.12m (up 20%), per the August 2026 release. The four FY2025 quarters add up to RM86.13m against RM87.0m audited. Release figures are unaudited, so use the annual report for full-year totals.

Our reading: the business is back in profit but the margin is thin: a 1.9% PBT margin in FY2025 and about 2% in 1H FY2026. Over the past three years, profit has depended on how fast new clinics fill up and how quickly patients use their prepaid packages. Anyone modelling this group should track contract liabilities and redemption commentary, not only revenue.

What are DC Healthcare’s house skincare brands?

The group has four in-house lines on the NPRA register. They are held by two group companies at the same Bandar Kinrara, Puchong address. We counted 34 active notifications in the NPRA Quest3+ cosmetic register (snapshot 3–5 Sep 2026): 24 under Ten Doctors Sdn Bhd and 10 under Klinik Dr Chong Sdn Bhd.

Source: NPRA Quest3+ notification register, snapshot 3–5 Sep 2026 (verified against the register). SKU counts are active notifications, not items on sale.

On the retail side, the brand web shop newbskincare.com listed 7 items on 25 Sep 2026, priced RM130–RM328. The clinic website links to it under “Purchase Our Product”. The newB Premium and Plant PDRN SKUs were not listed there and appear to be sold at the clinics. We found no Watsons, Guardian or Shopee listing (checked 25 Sep 2026).

How the range is sourced

Per NPRA, the flagship newB Premium range (11 SKUs) is made in Japan by Nihon Kolmar, and the other 23 SKUs are made in Malaysia by local contract manufacturers — 68% local, 32% imported. Two points are useful for anyone planning a clinic-owned line:

1. Split by price tier. The “made in Japan” story sits on the premium range, while the regimen basics and newer, higher-volume lines are made locally.
2. Continuity pays. Le Perfetto notifications from 2010–2011 are still active and the line was extended in 2025 — a long-running regimen that patients keep buying.

For the steps behind a clinic line (brief, formulation, notification, first order), see our step-by-step guide to launching a private-label skincare brand in Malaysia. For how the models differ, see OEM vs ODM vs private label.

Strengths and limitations of the model

Practical guidance: what clinic owners and suppliers can take from this

• Size the product line realistically. A 20-plus-clinic listed chain sells about RM4m of skincare a year, roughly RM170,000 per outlet using the AR2025 year-end outlet count (our calculation). Plan your first production orders against numbers like that, not against retail-brand targets.
• Plan notifications per factory. If one product is made in two plants, it needs two notifications, as the Dreamskin mask shows. Budget for this in time and cost. Our NPRA notification guide for 2026 covers the process.
• Match sourcing to the story you tell. If “made in Japan” or “made in Korea” is part of your premium pitch, only that tier needs it. Local manufacturing can handle the regimen basics at lower cost and with shorter lead times (see the cost of manufacturing a private-label skincare product).
• Questions to ask a contract manufacturer: Who owns the formula? Can the same formula go to other clients? What does it cost to notify each SKU per factory? What is the MOQ per SKU for a clinic-only launch?
• Red flag when you study competitors: a clinic that talks about a large product range but has only a handful of NPRA notifications. Always check the register yourself.

FAQ

Is DC Healthcare the same company as Dr Chong Clinic?
Yes. DC Healthcare Holdings Berhad is the listed parent, and Dr Chong Clinic is its main clinic brand, run through subsidiaries such as DC Lasers Sdn Bhd and Klinik Dr Chong Sdn Bhd. The group also runs Dr Chong Slimming and the new DC Plus Clinic. Check the latest company releases for which subsidiary runs which outlet.

How much does DC Healthcare earn from skincare?
RM3.97 million in FY2025, about 4.6% of group revenue, up from RM2.56 million in FY2024 (AR2025). Most revenue (87%) comes from aesthetic treatments. Skincare is disclosed as its own segment in the annual report, so you can track it each year.

Where is newB skincare made?
According to NPRA records (snapshot 3–5 Sep 2026), the 11 newB Premium SKUs are made in Japan. The newer Plant PDRN line, held by the same company, is made in Malaysia. Search the notification number on NPRA’s Quest3+ portal to confirm any single product.

Why did DC Healthcare make a loss in FY2024?
The company blamed a lower redemption rate for prepaid aesthetic treatments and higher expansion costs (marketing, operations, depreciation) as it grew from 13 to 19 aesthetic outlets. Loss after tax was RM19.65 million (AR2025, restated). It returned to profit in FY2025.

Is DC Healthcare profitable now?
Yes, though margins are thin. FY2025 profit after tax was RM0.21 million on RM87.0 million revenue. Q1 and Q2 FY2026 each showed a small pre-tax profit (RM0.32m and RM0.67m). Check the latest quarterly report on Bursa Malaysia for current figures.

Where is DC Healthcare listed?
On the ACE Market of Bursa Malaysia under stock code 0283 (DCHCARE), since 17 July 2023. Its IPO raised RM49.81 million at 25 sen a share.

Does Dr Chong Clinic sell its skincare online?
Partly. The newbskincare.com shop listed seven items (RM130–RM328) on 25 Sep 2026. The premium newB and Plant PDRN ranges were not on the shop and appear to be sold at the clinics. Product availability changes, so check the shop directly.

Sources and evidence

• DC Healthcare Holdings Bhd, Annual Report 2025 (revised): five-year financial highlights (p.7), MD&A revenue by segment (p.23), outlet count and milestones. Accessed 25 Sep 2026.
• DC Healthcare, Interim financial report for Q4 ended 31 Dec 2024: segmental note A9, reasons for the FY2024 decline. Accessed 25 Sep 2026.
• DC Healthcare releases: Q3 FY2025; Q1 FY2026 (25 May 2026); Q2 FY2026 (Aug 2026); clinic openings (24 Sep 2026).
• The Edge Malaysia: IPO pricing; ACE Market debut.
• NPRA, Quest3+ cosmetic notification search: holders Ten Doctors Sdn Bhd and Klinik Dr Chong Sdn Bhd, snapshot 3–5 Sep 2026.
• drchongclinic.com (branch list) and newbskincare.com (product list and prices), checked 25 Sep 2026.
• Google Maps listing capture of Malaysian clinics, 24 Sep 2026 (our dataset).

Limitations

This profile is based on public filings, company websites, the NPRA register and our own Google Maps capture. We did not visit clinics or factories, interview the company, or audit its accounts. Quarterly press-release figures are unaudited, and FY2024 numbers were restated in the AR2025. The NPRA register shows who is notified as the manufacturer, not order volumes or current production. Branch and product counts change often. Treat everything here as correct at the dates shown and check it again before you make a decision.

Update history

About the author
Farah Zainal is a contract manufacturing analyst who covers how Malaysian brands, clinics and suppliers source and launch products. Fact-checked by Daniel Yeoh.